No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + nivolumab Sensitive: A2 - Guideline pembrolizumab + nivolumab Sensitive : A2	pembrolizumab + nivolumab Sensitive: A2 - Guideline pembrolizumab + nivolumab Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	carboplatin + 5-fluorouracil Sensitive: A2 - Guideline carboplatin + 5-fluorouracil Sensitive : A2	carboplatin + 5-fluorouracil Sensitive: A2 - Guideline carboplatin + 5-fluorouracil Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	nivolumab + cetuximab Sensitive: A2 - Guideline nivolumab + cetuximab Sensitive : A2	nivolumab + cetuximab Sensitive: A2 - Guideline nivolumab + cetuximab Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 inhibitor Sensitive: A2 - Guideline PD-L1 inhibitor Sensitive : A2	PD-L1 inhibitor Sensitive: A2 - Guideline PD-L1 inhibitor Sensitive : A2
PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	PD-L1 inhibitor Sensitive: A2 - Guideline PD-L1 inhibitor Sensitive : A2	PD-L1 inhibitor Sensitive: A2 - Guideline PD-L1 inhibitor Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	Debio 1143 Sensitive: B - Late Trials Debio 1143 Sensitive : B	Debio 1143 Sensitive: B - Late Trials Debio 1143 Sensitive : B
CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
HRAS mutation	Squamous Cell Carcinoma of Head and Neck	HRAS mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
KMT2D mutation	Squamous Cell Carcinoma of Head and Neck	KMT2D mutation	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B

Squamous Cell Carcinoma of Head and Neck

Associations(290)

Associations
(290)